Croissy-Beaubourg, 6 December 2012 – Theradiag, a company specializing in theranostics and in vitro diagnostics, announces that, following the Open-Price Offering in France (“OPO”) and the global placement in France and abroad (notably excluding the United States of America) that closed on 4 December 2012, the total number of shares offered was almost twice oversubscribed. Total demand within the framework of the Initial Public Offering was €15.1 million.
Subsequently, the Company has decided to set the issuance price of its new shares at €5.80, at the upper end of the offering range. Furthermore, given the level of demand, the Company has decided to exercise 100% of the extension clause, thus taking the total value of the offering to €8.2 million.
“We are delighted to announce the success of our IPO on Alternext”, says Michel Finance, CEO of Theradiag. “We would like to thank all our staff and partners, and in particular our majority shareholder, Truffle Capital, as well as our new shareholders for their trust and support. The funds raised will provide us with additional means to finance our future: our development in theranostics and in new therapies for treating inflammatory and autoimmune diseases, cancer and AIDS, in addition to our existing Lisa-Tracker range, but also our microRNA platform. We will of course continue to enhance our innovative diagnosis proprietary product ranges and their international marketing”, adds Michel Finance.